Insurance limitations Many patients struggle with coverage restrictions
Available 24 hours a day, seven days a week
This can enable the development of novel redox-based therapeutics, beyond traditional ASMs which primarily aim to rectify neural excitatory/inhibitor imbalances at the synapse, to control neuroinflammation and in turn, epilepsy and/or its comorbidities
In 2015, Glenmark was the first to launch the DPP4 inhibitor, teneligliptin (Zita Plus and Ziten), followed by a FDC of teneligliptin + metformin (Zita-Met Plus and Ziten-M)
The active ingredient, medication, approval status, and availability should therefore be clearly distinguished
Semaglutide has not been documented to directly harm thyroid tissue or worsen autoimmune thyroid disease in clinical studies